Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing AstraZeneca and Daiichi Sankyo’s DESTINY trial data presented at ASCO 2023 on Enhertu in patients with HER2 advanced solid tumors

Ticker(s): AZN, DSKYF

Who's the expert?

Institution: Washington University School of Medicine

Medical Oncologist at the Siteman Cancer & Assistant Professor, Division of Medical Oncology, Section of Breast Oncology, Washington University School of Medicine.
Manages over 20 patients with HER2+ mBC.
PI of various clinical trials and works with colleagues on investigator initiated trials at her institution.

Interview Goal

On this call we will be discussing the potential of AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) in patients with HER2-expressing advanced solid tumors based on results from the DESTINY-PanTumor02 Phase II trial and the DESTINY-CRC02 Phase II trial that was recently presented at ASCO 2023.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.